Clinical characteristics in men with hemophilia and HCV infection
| Characteristic . | N = 121 . | . |
|---|---|---|
| Age at time of study∗ | ||
| Years | 54 (36-80 y) | |
| ≤50 | 62 (51.2%) | |
| >50 | 59 (48.8%) | |
| Race | ||
| White | 115 (95.0%) | |
| Non-White | 6 (5.0%) | |
| Hemophilia type | ||
| A | 95 (78.5%) | |
| B | 26 (21.5%) | |
| Inhibitor status | ||
| Current, ever | 13 (10.7%) | |
| Never | 108 (89.3%) | |
| HIV infection | 31 (25.6%) | |
| HCV antiviral therapy | 46 (38.0%) | |
| DAA based | 31 (67.4%) | |
| IFN/RBV based | 15 (32.6%) | |
| Platelets <100 000/μL | 9/93 (9.7%) | 0.173/100 py |
| ESLD | 24 (19.8%) | 0.365/100 py |
| HCC | 7 (5.8%) | 0.106/100 py |
| Past liver biopsy | 32 (26.4%) | |
| Metavir score (mean ± SEM) | 6.12 ± 0.52 | |
| Ishak score ≥5 | 10 (31.2%) | |
| Metavir score ≥F3 | 12 (37.5%) | |
| Liver transplantation | 3 (2.5%) | |
| Survival status | ||
| Alive | 87 (71.9%) | |
| Dead | 34 (28.1%) | |
| Cause of death | ||
| ESLD | 11 (32.3%) | |
| Bleeding | 9 (26.5%) | |
| HCC | 6 (17.6%) | |
| Sepsis | 3 (8.8%) | |
| Other | 5 (14.8%) |
| Characteristic . | N = 121 . | . |
|---|---|---|
| Age at time of study∗ | ||
| Years | 54 (36-80 y) | |
| ≤50 | 62 (51.2%) | |
| >50 | 59 (48.8%) | |
| Race | ||
| White | 115 (95.0%) | |
| Non-White | 6 (5.0%) | |
| Hemophilia type | ||
| A | 95 (78.5%) | |
| B | 26 (21.5%) | |
| Inhibitor status | ||
| Current, ever | 13 (10.7%) | |
| Never | 108 (89.3%) | |
| HIV infection | 31 (25.6%) | |
| HCV antiviral therapy | 46 (38.0%) | |
| DAA based | 31 (67.4%) | |
| IFN/RBV based | 15 (32.6%) | |
| Platelets <100 000/μL | 9/93 (9.7%) | 0.173/100 py |
| ESLD | 24 (19.8%) | 0.365/100 py |
| HCC | 7 (5.8%) | 0.106/100 py |
| Past liver biopsy | 32 (26.4%) | |
| Metavir score (mean ± SEM) | 6.12 ± 0.52 | |
| Ishak score ≥5 | 10 (31.2%) | |
| Metavir score ≥F3 | 12 (37.5%) | |
| Liver transplantation | 3 (2.5%) | |
| Survival status | ||
| Alive | 87 (71.9%) | |
| Dead | 34 (28.1%) | |
| Cause of death | ||
| ESLD | 11 (32.3%) | |
| Bleeding | 9 (26.5%) | |
| HCC | 6 (17.6%) | |
| Sepsis | 3 (8.8%) | |
| Other | 5 (14.8%) |
DAA, direct-acting antiviral agent; IFN/RBV, interferon and/or ribavirin; SEM, standard error of the mean.
As of 3 January 2023.